Clinical Genomics appoints two new VPs

Colorectal cancer screening test provider Clinical Genomics has appointed two new senior managers as part of its global expansion plan.

The company has named Warren Bingham as its new vice president of Asia-Pacific and Michele Houlsworth as its vice president of regulatory affairs.

Bingham joins Clinical Genomics from Given Imaging, where he managed the company’s Australia-New Zealand business for more than 10 years.

In his new role, Bingham will be responsible for growing the company’s existing business in Australia and opening new markets in Asia-Pacific.

Houldsworth has been promoted from the role of quality manager, a position she held since 2012. She has previously served as quality manager for SomnoMed and CathRx.

As VP of regulatory affairs, Houldsworth’s main goals will include winning pre-market approval for the company’s colorectal cancer blood test in the US. Clinical Genomics jointly developed the test with the CSIRO and recently agreed on the terms of a licensing agreement.

The new appointments form part of Clinical Genomics’ global expansion plan. CEO Dr Lawrence LaPointe will relocate from Australia to the US as part of this plan.

“Clinical Genomics is fortunate to attract the world class talents of Warren Bingham and Michele Houldsworth,” LaPointe said. “Since 2013 Clinical Genomics has created a world-beating product portfolio for the early detection of colorectal cancer, including our new blood test for colorectal cancer.”